De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Navamedic Beheer

Beheer criteriumcontroles 2/4

De CEO Navamedic's is Kathrine E. Andreassen, benoemd in Jan2019, heeft een ambtstermijn van 5.75 jaar. De totale jaarlijkse vergoeding van { bedraagt NOK 5.51M, bestaande uit 55.7% salaris en 44.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 4.37% van de aandelen van het bedrijf, ter waarde NOK 23.23M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.8 jaar en 1.8 jaar.

Belangrijke informatie

Kathrine E. Andreassen

Algemeen directeur

NOK 5.5m

Totale compensatie

Percentage CEO-salaris	55.7%
Dienstverband CEO	5.8yrs
Eigendom CEO	4.4%
Management gemiddelde ambtstermijn	5.8yrs
Gemiddelde ambtstermijn bestuur	1.8yrs

Recente managementupdates

Recent updates

Is Navamedic (OB:NAVA) Using Too Much Debt?

Sep 19

Here's Why Navamedic (OB:NAVA) Can Manage Its Debt Responsibly

Feb 18

Shareholders Can Be Confident That Navamedic's (OB:NAVA) Earnings Are High Quality

Nov 09

If You Had Bought Navamedic (OB:NAVA) Stock Three Years Ago, You Could Pocket A 166% Gain Today

Feb 18

Is Navamedic (OB:NAVA) Using Debt Sensibly?

Dec 07

Analyse CEO-vergoeding

Hoe is Kathrine E. Andreassen's beloning veranderd ten opzichte van Navamedic's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	NOK 25m
Mar 31 2024	n/a	n/a	-NOK 11m
Dec 31 2023	NOK 6m	NOK 3m	NOK 3m
Sep 30 2023	n/a	n/a	NOK 24m
Jun 30 2023	n/a	n/a	NOK 20m
Mar 31 2023	n/a	n/a	NOK 43m
Dec 31 2022	NOK 5m	NOK 3m	NOK 29m
Sep 30 2022	n/a	n/a	NOK 12m
Jun 30 2022	n/a	n/a	NOK 8m
Mar 31 2022	n/a	n/a	NOK 4m
Dec 31 2021	NOK 5m	NOK 2m	NOK 618k
Sep 30 2021	n/a	n/a	-NOK 7m
Jun 30 2021	n/a	n/a	-NOK 6m
Mar 31 2021	n/a	n/a	-NOK 8m
Dec 31 2020	NOK 4m	NOK 2m	-NOK 16m
Sep 30 2020	n/a	n/a	-NOK 22m
Jun 30 2020	n/a	n/a	-NOK 24m
Mar 31 2020	n/a	n/a	-NOK 26m
Dec 31 2019	NOK 3m	NOK 2m	-NOK 16m

Compensatie versus markt: De totale vergoeding ($USD 519.06K ) Kathrine E. } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Norwegian markt ($USD 314.60K ).

Compensatie versus inkomsten: De vergoeding van Kathrine E. is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Kathrine E. Andreassen (58 yo)

5.8yrs

Tenure

NOK 5,509,000

Compensatie

Ms. Kathrine E. Gamborg Andreassen serves as Director at Observe Medical Asa since June 13, 2019. Ms. Andreassen has been Chief Executive Officer of Navamedic ASA since January 1, 2019. She is Chairman of...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kathrine E. Andreassen	Chief Executive Officer	5.8yrs	NOK 5.51m	4.37% NOK 24.2m
Lars Hjarrand	Chief Financial Officer	4.8yrs	NOK 3.14m	1.62% NOK 9.0m
Tony Brejke	Chief Operating Officer	no data	geen gegevens	geen gegevens
Astrid J. Bratvedt	Chief Scientific Officer	5.8yrs	geen gegevens	3.4% NOK 18.8m
Karianne Olsen	Director of Sales & Marketing	no data	geen gegevens	0.16% NOK 872.1k
Ole Eriksen	Chief Business Development Officer	no data	geen gegevens	3.26% NOK 18.1m

5.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van NAVA is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Rune Wahl	Director	less than a year	geen gegevens	0.28% NOK 1.6m
Jostein Davidsen	Independent Chair of the Board	7.8yrs	NOK 235.00k	geen gegevens
Kjell-Erik Nordby	Director	less than a year	geen gegevens	geen gegevens
Asa Kornfeld	Director	1.3yrs	geen gegevens	geen gegevens
Annika Kollen	Independent Director	3.3yrs	NOK 210.00k	geen gegevens
Edmee Steenken	Independent Director	2.3yrs	NOK 210.00k	geen gegevens

1.8yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NAVA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw bestuur.

Navamedic Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Chief Executive Officer exercised options to buy kr2.2m worth of stock.

Director recently bought kr1.5m worth of stock

Navamedic ASA Elects Åsa Kornfeld as Members of its Board of Directors

No independent directors

Chief Financial Officer exercised options to buy kr2.1m worth of stock.

No independent directors

Recent updates

Chief Executive Officer exercised options to buy kr2.2m worth of stock.

Consensus EPS estimates fall by 12%

Director recently bought kr1.5m worth of stock

Second quarter 2024 earnings released: EPS: kr1.17 (vs kr0.92 loss in 2Q 2023)

Price target decreased by 7.1% to kr45.50

First quarter 2024 earnings released

An unknown buyer acquired unknown minority stake in Navamedic ASA (OB:NAVA) from Ingerø Reiten Investment Company As for NOK 95 million.

Consensus EPS estimates increase by 24%

Consensus EPS estimates fall by 28%, revenue upgraded

New minor risk - Earnings quality

Full year 2023 earnings released

Navamedic ASA to Report First Half, 2024 Results on Aug 16, 2024

Third quarter 2023 earnings released

Consensus EPS estimates increase by 10%

Is Navamedic (OB:NAVA) Using Too Much Debt?

Investor sentiment improves as stock rises 15%

Consensus EPS estimates fall by 53%

New minor risk - Financial position

Second quarter 2023 earnings: Revenues exceed analyst expectations

Consensus EPS estimates fall by 15%

Consensus EPS estimates fall by 16%, revenue upgraded

Navamedic ASA Elects Åsa Kornfeld as Members of its Board of Directors

First quarter 2023 earnings released

Price target increased by 8.7% to kr50.00

Here's Why Navamedic (OB:NAVA) Can Manage Its Debt Responsibly

Full year 2022 earnings released

Consensus EPS estimates increase by 20%, revenue downgraded

Navamedic ASA Launches Modifast in Norway

Navamedic ASA to Report Q3, 2023 Results on Nov 01, 2023

Price target increased to kr48.00

No independent directors

Consensus EPS estimates increase by 19%

Shareholders Can Be Confident That Navamedic's (OB:NAVA) Earnings Are High Quality

Third quarter 2022 earnings released

Is Navamedic (OB:NAVA) A Risky Investment?

Consensus forecasts updated

Price target decreased to kr44.00

Navamedic ASA Launches Forlaxgo®

Consensus EPS estimates increase by 50%

Consensus EPS estimates increase by 30%

Chief Financial Officer exercised options to buy kr2.1m worth of stock.

Navamedic ASA (OB:NAVA) acquired Impolin AB for SEK 55 million .

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analyst expectations

Navamedic ASA (OB:NAVA) agreed to acquire Impolin AB.

Price target increased to kr50.00

No independent directors

Here's Why Navamedic (OB:NAVA) Has A Meaningful Debt Burden

Full year 2021 earnings: Revenues exceed analyst expectations

Navamedic ASA launches SmectaGO - an innovative on-the-go product for treatment of diarrhea

Navamedic Asa Provides Revenue Guidance for the Full Year 2021 and 2022

Third quarter 2021 earnings released

We Think Navamedic (OB:NAVA) Can Stay On Top Of Its Debt

Second quarter 2021 earnings released: EPS kr0.20 (vs kr0.037 in 2Q 2020)

Navamedic ASA Announces the Launch of New Products in the Nordics

Navamedic Launches Mycontrol Support in Norway, A Free-Of-Charge Patient Support Program in Collaboration with Observia, Following A Successful Launch in Sweden

First quarter 2021 earnings released

Is Navamedic (OB:NAVA) Using Too Much Debt?

New 90-day high: kr29.00

Full year 2020 earnings released

If You Had Bought Navamedic (OB:NAVA) Stock Three Years Ago, You Could Pocket A 166% Gain Today

New 90-day high: kr22.60

Is Navamedic (OB:NAVA) Using Debt Sensibly?

Navamedic ASA to Report Q2, 2021 Results on Aug 13, 2021

New 90-day low: kr17.45

New 90-day low: kr18.20

Chief Executive Officer exercised options to buy kr2.3m worth of stock.

New 90-day low: kr18.50

Earnings released